Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMEPDF 81 3-Year EPS without NRI Growth Rate is 4.70% as of Mar. 2026, which is 96% above its 10-year median of 2.40. GuruFocus rates MEPDF with a GF Scoreâ„¢ of 81/100 and a GF Valueâ„¢ of $17.56 (Fairly Valued). The stock has 6 warning signs investors should review. Among 101 Medical Distribution companies, Medipal Holdings ranks better than 51.49% on this metric.
During the past 12 months, Medipal Holdings's average EPS without NRI Growth Rate was 19.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 4.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 7.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 2.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Medipal Holdings was 26.40% per year. The lowest was -29.50% per year. And the median was 2.40% per year.
Medipal Holdings (OTCPK:MEPDF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Medipal Holdings 3-Year EPS without NRI Growth Rate Related Terms
MEPDF vs MCK, COR, CAH: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Distribution subindustry, Medipal Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings 3-Year EPS without NRI Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's 3-Year EPS without NRI Growth Rate falls into.
Medipal Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 4.70% mean?
Medipal Holdings (MEPDF) has a 3-Year EPS without NRI Growth Rate of 4.70% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Medipal Holdings and its competitors. This is 96% above median its historical median of 2.40. According to the industry distribution chart, Medipal Holdings ranks #49 out of 101 companies in the Medical Distribution industry, placing it in the top 48.5%.
Is Medipal Holdings' 3-Year EPS without NRI Growth Rate too high?
Medipal Holdings' current 3-Year EPS without NRI Growth Rate of 4.70% is 96% above median its 10-year median of 2.40. The Medical Distribution industry median 3-Year EPS without NRI Growth Rate is 2.60. Medipal Holdings' value of 4.70% is 80.8% above this industry median. Based on the distribution chart, Medipal Holdings ranks #49 out of 101 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Scoreâ„¢ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' 3-Year EPS without NRI Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #49 out of 101 companies for 3-Year EPS without NRI Growth Rate. This puts Medipal Holdings in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 2.60. Medipal Holdings' value of 4.70% is 80.8% above this benchmark. While the company's 10-year median is 2.40 vs. the industry median of 2.60, Medipal Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Distribution company?
The median 3-Year EPS without NRI Growth Rate among Medical Distribution companies is 2.60, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current 3-Year EPS without NRI Growth Rate of 4.70% is 80.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Medipal Holdings and its competitors. For the Medical Distribution industry, the median 3-Year EPS without NRI Growth Rate is 2.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current 3-Year EPS without NRI Growth Rate is 4.70%, which is 96% above median its own 10-year median of 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MEPDF) is currently considered Fairly Valued. The stock's GF Value™ is $17.56, compared to a current price of $18.35 — trading 4.5% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 4.70%, which is 96% above median its 10-year median of 2.40 and 80.8% above the Medical Distribution industry median of 2.60. Medipal Holdings' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Medipal Holdings (MEPDF), the current 3-Year EPS without NRI Growth Rate is 4.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MEPDF) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $18.35 is trading 4.5% above its estimated GF Value™ of $17.56.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MEPDF:
3-Year EPS without NRI Growth Rate: 4.70% (96% above median its 10-year median of 2.40)
GF Value™: $17.56 vs. price of $18.35 (4.5% above fair value)
Industry Position: 80.8% above the Medical Distribution median (#49 of 101)
No single metric tells the full story. See the MEPDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
81GF Score
Get the complete analysis for MEPDF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEPDF has been successfully added to your 
